Our Services
Medical Information
Helpful Resources
Published on: 7/2/2026
GLP-1 agonists like Ozempic and Wegovy can cause rapid weight loss, but up to 40% of that loss may come from muscle mass—reducing metabolism, strength, and blood sugar control. Resistance training is essential during GLP-1 therapy to stimulate muscle protein synthesis, preserve bone density, and maintain resting metabolic rate.
Key factors for an effective resistance training program on GLP-1 medications include:
If you're experiencing unexpected fatigue, weakness, dizziness, or other symptoms while on GLP-1 therapy, these could signal muscle loss, nutrient deficiencies, or other issues worth addressing early. Understanding what's happening in your body is the first step toward protecting your health during rapid weight loss. Take a free, instant, online symptom check to better understand your symptoms and confidently navigate your next steps.
Reviewed for medical accuracy: 07/02/2026
Losing weight with GLP-1 receptor agonists (such as semaglutide or liraglutide) can be highly effective. However, rapid weight loss often includes not only fat but also valuable lean muscle mass. Preserving that muscle is critical for your metabolism, strength, and overall health. In this article, we'll explore why resistance training is non-negotiable when you're on a GLP-1 program, all grounded in credible research.
GLP-1 (glucagon-like peptide-1) agonists work by:
Clinical trials in journals like The New England Journal of Medicine have shown average weight losses of 10–15% of body weight over 6–12 months. But without countermeasures, up to 25% of that loss can come from skeletal muscle.
Resistance training (RT) includes weightlifting, bodyweight exercises, resistance bands, or machines. Its benefits during GLP-1 therapy include:
A 2022 study in The American Journal of Clinical Nutrition compared two groups of adults on calorie-restricted diets (one with resistance training, one without). The RT group lost the same amount of total weight but preserved 60% more lean mass.
Another trial published in Obesity Reviews showed that GLP-1 users who added structured exercise (including RT) retained significantly more muscle and maintained higher resting metabolic rates than non-exercisers.
To optimize lean muscle mass preservation while on GLP-1 therapy, follow these guidelines:
While GLP-1 medications often reduce appetite, your body's protein needs remain high to support muscle repair and growth.
Track both your weight loss and body composition to ensure you're losing fat, not muscle.
If you experience any serious side effects—severe nausea, dizziness, chest pain—or if you're unsure how to start a resistance program, it's crucial to get medical advice. If you're experiencing concerning symptoms and want immediate guidance on whether to seek care, try using a Medically approved LLM Symptom Checker Chat Bot for quick, AI-powered insights before your doctor's appointment.
Always speak to a doctor before making major changes to your medication, diet, or exercise routine. They can tailor recommendations based on your medical history and current health status.
By combining GLP-1 therapy with structured resistance training and smart nutrition, you'll protect your lean muscle mass, support a healthy metabolism, and set yourself up for long-term weight management success. Remember: speak to your doctor about any concerns or life-threatening symptoms to ensure you're on the safest, most effective path.
(References)
* Shao, J., Ma, Q., Zhu, J., & Li, R. (2024). Exercise for the prevention of sarcopenia in individuals treated with GLP-1 receptor agonists for weight loss. *Current Opinion in Clinical Nutrition and Metabolic Care*, *27*(1), 127-133.
* Muscogiuri, G., Palma, M., Alfieri, M. R., Palomba, L., Pugliese, G., Lauria, D. G., ... & Barrea, L. (2024). Strategies to Mitigate Sarcopenia in Obese Patients Undergoing Pharmacological Weight Loss: A Narrative Review. *Nutrients*, *16*(3), 395.
* He, W., Wang, F., Li, Z., Guo, S., Ma, J., Wang, J., ... & Li, C. (2024). Tirzepatide for Weight Loss: A Focus on Body Composition and Muscle Preservation. *Pharmaceuticals*, *17*(2), 232.
* Tarnowski, M., & Grygiel-Górniak, B. (2023). Sarcopenia in obesity during treatment with GLP-1 receptor agonists: current evidence and future perspectives. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, *16*, 2803–2814.
* Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Gribsholt, S. B., & Haase, M. (2023). Body Composition Changes With Semaglutide 2.4 mg for Weight Loss: A Systematic Review and Meta-Analysis. *The Journal of Clinical Endocrinology & Metabolism*, *108*(12), 3042–3051.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.